Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps

April 24, 2014 Xeris Pharmaceuticals, Inc., a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today the dosing of the first subject in a Phase 2 clinical study of the company’s stable liquid glucagon in an Insulet Corporation OmniPod® infusion pump in patients with type 1 diabetes under a new US Investigational New Drug (IND) …

Stemline Therapeutics Announces FDA Acceptance of Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors

April 8, 2014 Stemline Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides engineered …